{
  "id": "fda_guidance_chunk_0308",
  "title": "Introduction - Part 308",
  "text": "Food Safety and Applied Nutrition Center for Tobacco Products Center for Veterinary Medicine June 2024 Contains Nonbinding Recommendations Draft — Not for Implementation TABLE OF CONTENTS I. INTRODUCTION ............................................................................................................. II. BACKGROUND ............................................................................................................... III. PROCESSES AND PRACTICES APPLICABLE TO BIORESEARCH MONITORING INSPECTIONS ................................................................................................. A. BIMO Processes and Practices ..................................................................................................... B. Types of Inspections ....................................................................................................................... C. International Inspections ............................................................................................................... IV. BEST PRACTICES FOR COMMUNICATION BETWEEN THE FDA AND INDUSTRY IN ADVANCE OF, DURING, OR AFTER AN INSPECTION ......................... A. Pre-announcement Notice and Communication ......................................................................... B. Inspection Timeframe and Duration ............................................................................................ C. Communication During An Inspection ........................................................................................ D. Communication After An Inspection ........................................................................................... E. Who to Contact at FDA for More Information? ......................................................................... RESOURCE GUIDE ............................................................................................................................ Contains Nonbinding Recommendations Draft — Not for Implementation Processes and Practices Applicable to Bioresearch Monitoring Inspections Guidance for Industry1 This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page. I. INTRODUCTION FDA is issuing this guidance to comply with section 3612(b)(2) of the Food and Drug Omnibus Reform Act of 2022 (FDORA), enacted as part of the Consolidated Appropriations Act, 2023.2 FDORA directs FDA to issue guidance describing the processes and practices applicable to inspections of sites and facilities described in section 704(a)(5)(C)(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act),3 to the extent not specified in existing publicly available FDA guides and manuals for such inspections. These establishments4 are inspected under FDA’s Bioresearch Monitoring (BIMO) program in accordance with section 704(a)(5) of the FD&C Act. Specifically, this guidance addresses the following (to the extent not publicly available in FDA guides and manuals): the types of records and information required to be provided, best practices for communication between FDA and industry in advance of or during an inspection or request for records or other information, and other inspections-related conduct.5 In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 412608,
  "end_pos": 414144,
  "tokens": 512,
  "tags": [
    "safety",
    "regulatory",
    "data"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "mandatory",
  "created_at": "2025-10-23T02:25:44.700Z"
}